Phase II Trial of Weekly Nab-paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) Trial 1301

E-resources

Peer reviewed

Phase II Trial of Weekly Nab-paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group (KTOSG) Trial 1301

Sakata, Shinya; Saeki, Sho; Okamoto, Isamu; Otsubo, Kohei; Komiya, Kazutoshi; Morinaga, Ryotaro; Yoneshima, Yasuto; Koga, Yuichiro; Enokizu, Aimi; Kishi, Hiroto; Hirosako, Susumu; Yamaguchi, Emi; Aragane, Naoko; Fujii, Shinji; Harada, Taishi; Iwama, Eiji; Semba, Hiroshi; Nakanishi, Yoichi; Kohrogi, Hirotsugu

Lung cancer (Amsterdam, Netherlands), 09/2016, Volume: 99

Journal Article

Highlights • This is a phase II study of nab-paclitaxel in patients with previously treated NSCLC. • The ORR was 31.7%, which met the primary objective of the study. • The median PFS was 4.9 months and the median OS was 13.0 months. • Hematologic toxicities of grade 3 or 4 was neutropenia (19%) and leukopenia (17%). • Nab-paclitaxel showed acceptable toxicity and favorable ORR.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme